Leadership
As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.
Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, In Vivo investigates.
The sixth annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.
Exec summary will go here...Exec summary will go here...Exec summary will go here...Exec summary will go here...Exec summary will go here...Exec summary will go here...
Exec summary XXXXXXX
Patrick Alexandre, Crossject CEO, discusses crucial developments happening for Zeneo, a needle-free injector, functioning intramuscularly to administer medication in a tenth of a second
Christopher Anzalone is spearheading Arrowhead Pharmaceuticals' transformation from a development-focused to a commercial-stage biotech. The CEO touts an “almost plug and play” platform, a derisked development strategy and a busy pipeline with vast potential.
Christopher Anzalone is spearheading Arrowhead Pharmaceuticals' transformation from a development-focused to a commercial-stage biotech. The CEO touts an “almost plug and play” platform, a derisked development strategy and a busy pipeline with vast potential.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
John Lepore, CEO of ProFound Therapeutics and CEO-partner at Flagship Pioneering, discusses the vast possibilities for the human atlas, the benefits of strategic partnering and knowing when to walk away from a project.
King’s College London has released a freely available ‘Human Gut Microbiome Atlas’ to help researchers better understand how microorganisms in the gut impact disease.
It has been quite a year for German biotech Tubulis, and CEO Dominik Schumacher tells In Vivo that the group has the potential to be “a really meaningful, sizable leader” in the antibody-drug conjugate space.
It has been quite a year for German biotech Tubulis, and CEO Dominik Schumacher tells In Vivo that the group has the potential to be “a really meaningful, sizable leader” in the antibody-drug conjugate space.
Taylor Wessing investment partners share their thoughts about market trends, the surge in AI interest and the new UK government’s approach to the life sciences agenda.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In her role as Boehringer's senior vice president and global head of Development Sciences, Xiaorong He emphasizes patient-centric innovation and sustainability. She is committed to incorporating patient insights into product development and advancing eco-friendly practices within the company's R&D pipeline.
Together, Merck’s heads of oncology and head of digital health outline their cross-functional strategy to enhance care for cancer patients through digital tools.
Roman Thomas, co-founder and CEO of DISCO Pharmaceuticals, outlines how the company’s surfaceome technology could disrupt drug discovery in oncology.